For example, JQ1, a tert-butyl synthetic precursor of OTX015, is a prototype BET inhibitor (BETi), which competitively binds to the bromodomain and displaces BRD4 from super-enhancers for the MYC oncogene [16, 27–30] thus impeding tumor cell growth in various malignancies, including MM [16, 31–36]. This evidence concerns the gene BRD4 and Miyoshi myopathy.